Thyroid-associated ophthalmopathy (TAO) is an autoimmune component of Graves' disease for which no currently available medical therapy provides reliable and safe benefit. Based on insights generated experimentally over the past several decades, the insulin-like growth factor-I receptor (IGF-IR) has been implicated in the pathogenesis of TAO. Furthermore, an IGF-IR inhibitor, teprotumumab, has emerged from 2 clinical trials as a promising treatment for active, moderate to severe TAO. This brief review intends to provide an overview of the rationale underlying the development of teprotumumab for this disease. It is possible that teprotumumab will soon take its place in our therapeutic armamentarium for active TAO.

中文翻译：

---

甲状腺相关性眼病中的Teprotumumab：治疗性胰岛素样生长因子-I受体抑制的原理。

甲状腺相关性眼病（TAO）是格雷夫斯病的一种自身免疫性成分，目前尚无药物可提供可靠和安全的益处。根据过去几十年实验得出的见解，胰岛素样生长因子-I受体（IGF-IR）与TAO的发病有关。此外，IGF-1R抑制剂teprotumumab从两项临床试验中出现，作为治疗活跃，中度至重度TAO的有希望的疗法。这篇简短的综述旨在概述teprotumumab对该疾病的发展基础。teprotumumab可能很快会在我们的治疗性武器库中取代活性TAO。